Truist Securities has reiterated a Buy rating on Hinge Health Inc (NYSE: HNGE) and established a $63.00 price target following the company’s fourth-quarter 2025 reporting. The $63 target equates to a meaningful premium relative to the current share price of $37 and aligns with a wider set of analyst targets spanning $48 to $72.
Truist analyst Jailendra Singh reaffirmed the firm’s positive stance after a post-quarter call with Hinge Health’s management team in which the company’s recent performance and near-term plans were discussed. While Hinge Health has not posted profitability over the last twelve months, InvestingPro data referenced by analysts indicates an expectation that the company will reach profitability this year, with a forecasted EPS of $1.57 for fiscal year 2025.
During the post-quarter discussions, management reviewed the fourth-quarter 2025 results and provided outlook commentary for 2026 and the first quarter of 2026. The conversation also covered dynamics around the recent selling season and broader trends in industry consolidation. In the trailing twelve months, Hinge Health generated $534.39 million in revenue, and forecasts point to roughly 47% revenue growth for FY2025.
Truist’s published note highlighted what it characterized as "Multiple Upside Drivers to An Already Strong 2026 Guidance," signaling the firm’s confidence in the company’s forward-looking projections. The research write-up included a question-and-answer style section based on the management call, although the note did not reproduce those exchanges verbatim.
Hinge Health’s reported fourth-quarter 2025 results included an earnings surprise and continued top-line momentum. The company posted earnings per share of $0.49, beating the forecasted $0.14 by 250%, and reported quarterly revenue of $171 million, representing 46% year-over-year growth.
Several other brokerages adjusted their price targets and reiterated positive ratings following the quarter:
- Barclays lowered its price target to $52 from $60 while maintaining an Overweight rating, citing improved billings and higher engagement metrics.
- RBC Capital cut its target to $50 from $60 and kept an Outperform rating, noting solid revenue performance and margin expansion.
- Citizens reiterated a Market Outperform rating with a $65 price target, pointing to the company’s strong results and what it described as efficient guidance for 2026.
- Needham kept a Buy rating and a $59 price target, emphasizing Hinge Health’s strong fiscal 2025 finish and its encouraging FY26 guidance.
Taken together, the analysts’ revisions and reiterations reflect a broadly positive stance on Hinge Health despite some downward adjustments to certain price targets. The commentary from multiple firms referenced improved billings, engagement metrics, revenue strength, and margin progress as drivers behind their maintained constructive outlooks.
While the analysis and management commentary convey optimism about growth and margin trajectories, the company’s trailing lack of profitability remains a datapoint that analysts are watching closely as forecasts point toward a profitable FY2025. The research note and accompanying Q&A indicate continued focus on execution against 2026 guidance and how recent selling season trends and industry consolidation may influence outcomes.
Investors and market participants will likely monitor upcoming quarterly disclosures and any additional detail management provides on billings, engagement measures, and margin expansion to assess whether the multiple upside drivers Truist referenced materialize within the company’s guidance horizon.